We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Clinical Trials Advisor (CTA) is designed especially for the clinical trials professional charged with gathering submission-quality data while protecting the safety and welfare of study subjects.
With 12 issues a year, you can be confident that you'll stay abreast of the latest developments in global clinical trial trends, changes in trial endpoints and regulations that govern drug and medical device clinical trials.
Each issue of Clinical Trials Advisor provides:
Essential industry news, including international news, to keep you fully compliant
Tested techniques to keep your clinical trials safe, compliant and efficient
Your subscription also includes access to The Clinical Trials Advisor Regulatory Resource Center — a one-stop location for all the guidance, regulation and laws you’ll need to comply with U.S and international clinical trial requirements. The resource center is updated continuously and available to you around the clock.
Our 100% Money-Back Guarantee
There’s absolutely no risk to you. You get our 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Clinical Trials Advisor, you may cancel your subscription and receive a full refund. No questions asked.
So, why wait? Become a subscriber to Clinical Trials Advisor today. It couldn’t be easier.
Monthly, 12 issues/year. Electronic delivery.
$745 $545
Bonus
Subscribe to Clinical Trials Advisor NOW and save $200 off the regular one-year price of $645 — plus receive a FREE copy of our webinar CD, Electronic Informed Consent for Biobanks – a $287 value!
Key Benefits
LINKS TO KEY DOCUMENTS — Need to read regulatory references, guidances, enforcement actions, and other documents? Simply click on the source documents in your electronic issue.
ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.